In the Phase 2 obesity trial published in the New England Journal of Medicine, the highest arm reached 24.2 percent average body weight loss at 48 weeks, and the curve had not flattened by the end
SELECT Trials Groundbreaking Results In 2023, in a landmark finding, the SELECT trial showed that adults with overweight or obesity but without diabetes, who had previously experienced a heart attack, stroke and/or had peripheral artery disease, taking semaglutide had a 20% reduction in major adverse cardiac events such as heart attacks and strokes compared to those on placebo over the course of 3 years
Its more likely to be covered if you have obesity-related health conditions like diabetes or high blood pressure
This is a series of Phase 3 trials studying retatrutide across multiple conditions: TRIUMPH-1 : Obesity (basket trial with nested OSA and OA protocols) TRIUMPH-2 : Obesity in type 2 diabetes population (with nested OSA) TRIUMPH-3 : Weight management in cardiovascular disease population TRIUMPH-4 : Obesity with knee osteoarthritis (completed results December 2025) Additional trials covering MASLD (metabolic dysfunction-associated steatotic liver disease), cardiovascular/renal outcomes, chronic low back pain, and weight maintenance TRANSCEND program: Dedicated type 2 diabetes trials (separate from TRIUMPH) TRIUMPH-4 was the first Phase 3 trial to report results, announced in December 2025
The pH balanced formula maintains healthy skin
Rather than guessing whether your symptoms are normal, you can get clinical guidance specific to your situation
